Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds
Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds
Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk's new weight loss drug monlunabant shows promising results but raises concerns due to increased risk of psychiatric side effects compared to placebo.
The next big market for weight-loss drugs: children
Novo Nordisk's Saxenda can significantly reduce children's BMI, showing potential for FDA approval in a market with currently no approved obesity medications for children.